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The L1 and L2 capsid proteins of animal and human papillomaviruses (HPVs) can self-assemble into virus-like particles
(VLPs) that closely resemble native virions. The use of different animal models shows that VLPs can be very efficient at
inducing a protective immune response. However, studies with infectious HPV virions and VLPs of different HPV types
indicate that the immune response is predominantly type-specific. We have generated a diploid yeast strain that coexpresses
the L1 and L2 capsid proteins of both HPV-6b and HPV-16, and we have purified fully assembled VLPs banding in a cesium
chloride gradient at the expected density of 1.29–1.3 mg/ml. Experimental evidence strongly indicated that the four proteins
coassembled into VLPs. Western blot analysis, using anti-HPV-6 and anti-HPV-16 L1-specific monoclonal antibodies and
type-specific L2 antisera, demonstrated that all four proteins copurified. Most importantly, immunoprecipitation experiments,
carried out using type-specific anti-L1 monoclonals and either total yeast cell extracts or purified VLPs, confirmed the
interaction and the formation of covalent disulfide bonds between the two L1 proteins. Finally, HPV-6/16 VLPs administered
to mice induced conformational antibodies against both L1 protein types. These results suggest that coexpression of
different capsid proteins may provide new tools for the induction of antibodies directed against multiple HPV types. © 2002ly; yeaINTRODUCTION
A promising strategy aimed at inducing an immune
response capable of neutralizing papillomavirus (PV) in-
fections is the use of virus capsid proteins as antigens.
In the case of genital human papillomaviruses (HPVs),
this approach is hampered by the lack of any in vivo or in
vitro source of sufficient amounts of native virus. To
overcome the problem, heterologous expression sys-
tems have been used extensively to obtain large quan-
tities of capsid proteins and to allow the analysis of their
structural and immunological properties. Expression of
the major capsid protein late 1 (L1) from different PV
types using prokaryotic (Li et al., 1997; Nardelli-Haefliger
et al., 1997), baculovirus (Kirnbauer et al., 1992, 1996;
Rose et al., 1993; Suzich et al., 1995; Touze et al., 1998;
Volpers et al., 1994), yeast (Greer et al., 2000; Hofmann et
al., 1995, 1996; Jansen et al., 1995; Neeper et al., 1996;
Sasagawa et al., 1995), and mammalian expression sys-
tems (Hagensee et al., 1993, 1994; Zhou et al., 1993)
demonstrates that this protein can self-assemble into
virus-like particles (VLPs). Coexpression of the minor
capsid protein late 2 (L2) is not strictly necessary to
1 These authors contributed equally to this work.335obtain VLPs, but its presence increases the efficiency of
particle formation (Hagensee et al., 1993; Kirnbauer et al.,
1993; Sasagawa et al., 1995; Zhou et al., 1993).
Although capsomeric VLP subunits can induce in vitro
neutralizing antibodies (Fligge et al., 2001; Rose et al.,
1998), fully assembled VLPs meet most of the criteria that
make them ideal surrogates of native virions. They re-
semble infectious particles by ultrastructural analysis
(Hagensee et al., 1994), elicit high titers of virus-neutral-
izing antibodies, and bind to the putative receptor on the
surface of mammalian cells (Muller et al., 1995; Qi et al.,
1996; Roden et al., 1994; Unckell et al., 1997; Volpers et
al., 1995). Most notably, the results obtained with animal
models demonstrate that prophylactic immunization with
VLPs can be very effective in vivo. Cottontail rabbits,
calves, and dogs immunized with L1 VLPs are protected
from subsequent challenge with the homologous PV
(Jansen et al., 1995; Kirnbauer et al., 1996; Suzich et al.,
1995), and passive transfer of immune sera confers pro-
tection to naive animals (Jansen et al., 1995; Suzich et al.,
1995), indicating that an antibody-mediated response
plays a major role in preventing virus infection. The
efficacy of VLP-based anti-HPV vaccine candidates can-
not be evaluated in animals, since these viruses exhibit
a high degree of species specificity. Antibody-mediatedElsevier Science (USA)
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virus neutralization has therefore been studied using
either in vitro assays (Roden et al., 1996a; Smith et al.,
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1995) or xenograft systems, which allow propagation of
infectious virus of specific HPV types (Bonnez et al.,
1993, 1998; Christensen et al., 1990; Christensen and
Kreider, 1990; Kreider et al., 1987). The primary conclu-
sion which has been drawn from these experiments is
that immunization with HPV VLPs evokes a neutralizing
immune response which is predominantly type-specific
(Christensen et al., 1990, 1994; Roden et al., 1996a,b;
Rose et al., 1994; White et al., 1998). Therefore, an ideal
anti-HPV vaccine aimed at protection from different HPV
types should necessarily include VLPs able to elicit an
immune response directed against all the serotypes of
interest.
On the basis of this background, we attempted to
obtain VLPs resulting from the coassembly of capsid
proteins of two different HPV types in a single Saccha-
romyces cerevisiae strain. Therefore, we generated a
yeast diploid strain that coexpresses the HPV-6 and
HPV-16 L1 and L2 genes, and we purified assembled
VLPs which were used to evaluate possible interactions
between the different capsid proteins.
RESULTS
HPV type-specific detection of capsid proteins
expressed in yeast
Since our experimental approach implied the coex-
pression of closely related capsid proteins in the same
yeast cell, we initially wanted to check that the antibod-
ies available in our laboratory could unambiguously rec-
ognize the HPV-6 and HPV-16 L1 and L2 proteins accord-
ing to their type specificity. To accomplish this, the four
L1 and L2 genes were cloned in the episomal pBS24.1
vector and expressed independently in the S. cerevisiae
JSC310 strain. Figure 1 shows the results of a Western
blot analysis of total cell extracts prepared from the
recombinant strains incubated with specific anti-HPV-6
or -HPV-16 L1 monoclonal antibodies (Mabs) and with
HPV-6 or HPV-16 L2 antisera. In all cases, HPV type-
specific bands were detected, although a weak cross-
reactivity could be seen for both the L2 antisera. While
the HPV-6 and HPV-16 L1 Mabs identified proteins with
the expected molecular weight of about 55 kDa, the L2
proteins, as previously reported (Doorbar and Gallimor,
1987; Firzlaff et al., 1988), showed an electrophoretic
mobility corresponding to approximately 72–75 kDa, in-
stead of the 55 kDa predicted on the basis of their amino
acid sequences.
Expression of HPV-6 and HPV-16 L1 and L2 proteins
in a single yeast strain
The next experimental step consisted in obtaining two
haploid strains, each expressing an L1 protein type and
the heterologous L2 protein. Since the two haploids were
generated using S. cerevisiae strains which had oppo-
site mating types, their mating resulted in a diploid strain
which expressed the four HPV-6 and HPV-16 L1 and L2
proteins. In order to obtain expression of the exogenous
genes under identical culture conditions, each of them
was cloned within the same expression cassette based
on the ADH2/GAP glucose-repressible hybrid promoter
and the TMF transcriptional termination sequence. The
HPV-6 and HPV-16 L1 proteins were expressed by
means of the episomal expression vector pBS24.1. Ex-
pression of the HPV-6 and HPV-16 L2 proteins was in-
stead obtained by cloning the expression cassette into
an integrative plasmid suitable for insertion into the lys2
locus of the haploid strain genome. As a consequence of
this cloning strategy, the L1 and L2 gene copy numbers
in the haploid strains were different, and this resulted in
higher expression levels of the L1 proteins. This was to
resemble the ratio of L1 to L2 observed in native HPV
virions, which has been estimated over a range of 5:1 to
30:1 (Kirnbauer et al., 1993).
Table 1 lists the parental yeast strains used as well as
the recombinant haploid strains obtained and the diploid
strains resulting from their mating. Selection of the AB/
JS-4L diploid strain required an additional selective
marker in the haploid JSC310-6L2int strain. This was
obtained by inactivating the endogenous Ade2 gene by
means of an integration plasmid (see Materials and
Methods). Western blot analysis (Fig. 2) proved that both
haploid strains AB110-6L1/16L2 and JSC310-16L1/6L2 ex-
pressed the exogenous genes and that the expression of
FIG. 1. Western blot analysis of cell extracts from yeast strains
expressing the HPV-6 and HPV-16 capsid proteins. Equivalent amounts
of total cell extracts from the parental JSC310 strain (lanes 1) and
different recombinant strains (lanes 2 and 3) were separated by 10%
SDS–PAGE, electrotransferred to nitrocellulose filters, and incubated
with the H6.C6 (a) or the H16.H5 (c) type-specific anti-L1 Mabs and with
HPV-6L2 (b) or HPV-16L2 (d) antisera. Lanes 2a and 2c, JSC310-6L1epi;
lanes 3a and 3c, JSC310-16L1epi; lanes 2b and 2d, JSC310-6L2epi;
lanes 3b and 3d, JSC310-16L2epi. Molecular mass standards (in kDa)
are indicated. All figures have been assembled by using Adobe Pho-
toshop 6.0 and Macromedia FreeHand 9.0 programs for Macintosh.
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all four proteins was stably maintained in the resulting
AB/JS-4L diploid strain.
To acquire information about significant interactions
between the two major L1 capsid proteins, we performed
immunoprecipitation experiments using total yeast cell
extracts. Since it has been shown previously that forma-
tion of disulfide-bonded trimers of L1 molecules is a
prerequisite to obtain fully assembled VLPs (Sapp et al.,
1998), the immunoprecipitated products were analyzed
by PAGE performed under nonreducing conditions (Fig.
3). The results obtained confirmed that conformationally
dependent anti-L1 type-specific Mabs could selectively
immunoprecipitate HPV-6 or HPV-16 L1 trimers (Figs. 3a
and 3b, lanes 1 and 2). As a control, cultures of the
haploid clones were mixed before the cell extract was
prepared, and again, under identical experimental con-
ditions, the anti-HPV-6 and the anti-HPV-16 L1 Mabs
were able to immunoprecipitate only the related protein
trimer (Figs. 3a and 3b, lanes 3). However, when the cell
extract of the diploid strain AB/JS-4L was used, the two
Mabs could immunoprecipitate L1 trimers which reacted
against both L1 type-specific Mabs (Figs. 3a and 3b,
lanes 4). Identical results were observed when the L1
portion, which is not organized as trimers, was detected
(Figs. 3c and 3d).
TABLE 1
Parental and Recombinant Yeast Strains with Genotypes and HPV Expressed Genes
Yeast strain Genotype
Episomal
HPV gene
Integrated
HPV gene
JSC310 MATa leu2-3 ura3-52 prb1-1122 pep4-3 prc1-407 adr1::DM15 cir°
AB110 MAT leu2-3-112 ura3-52 pep4-3 his4-580 cir°
JSC310-6L1epi MATa prb1-1122 pep4-3 prc1-407 adr1::DM15 cir° 6L1
JSC310-16L1epi MATa prb1-1122 pep4-3 prc1-407 adr1::DM15 cir° 16L1
JSC310-6L2epi MATa prb1-1122 pep4-3 prc1-407 adr1::DM15 cir° 6L2
JSC310-16L2epi MATa prb1-1122 pep4-3 prc1-407 adr1::DM15 cir° 16L2
JSC310-6L2int MATa leu2-3 ura3-52 prb1-1122 lys2 pep4-3 prc1-407 adr1::DM15 cir° 6L2
AB110-16L2int MAT leu2-3-112 ura3-52 pep4-3 lys2 his4-580 cir° 16L2
JSC310-16L1/6L2 MATa prb1-1122 lys2 prc1-407 pep4-3 ade2 adr1::DM15 cir° 16L1 6L2
JSC310-16L1C/6L2 MATa prb1-1122 lys2 prc1-407 pep4-3 ade2 adr1::DM15 cir° 16L1C 6L2
AB110-6L1/16L2 MAT pep4-3 lys2 his4-580 cir° 6L1 16L2
AB110-6L1C/16L2 MAT pep4-3 lys2 his4-580 cir° 6L1C 16L2
AB/JS-4L MATa/MAT PRB1/prb1-1122 lys2/lys2 PRC1/prc1-407 pep4-3/pep4-3
HIS4/his4-580 ADR1/adr1::DM15 cir°
6L1-16L1 6L2-16L2
AB/JS-4LC MATa/MAT PRB1/prb1-1122 lys2/lys2 PRC1/prc1-407 pep4-3/pep4-3
HIS4/his4-580 ADR1/adr1::DM15 cir°
6L1C-16L1C 6L2-16L2
FIG. 2. Western blot analysis of cell extracts from recombinant
haploid and diploid yeast strains. Total cell extracts were separated by
10% SDS–PAGE, electrotransferred to nitrocellulose filters, and incu-
bated with anti-HPV-6 L1 (a) and anti-HPV-16 L1 (c) Mabs and with
HPV-6 L2 (b) and HPV-16 L2 (d) antisera. Lanes 1, AB110-6L1/16L2;
lanes 2, JSC310-16L1/6L2; lanes 3, AB/JS-4L; lanes 4, JSC310-6L2epi;
lanes 5, JSC310-16L2epi. Arrows in b and d indicate the bands thought
to represent the L2 proteins. Molecular mass standards (in kDa) are
indicated.
FIG. 3. Immunoprecipitation analysis of total yeast cell extracts. Total
yeast cell extracts were immunoprecipitated by using the anti-L1 type-
specific conformationally dependent Mabs H6.B10.5 and H16.V5 and
subjected to Western blot analysis to detect type-specific L1 (a–d).
Immunoprecipitates were fractionated under nonreducing conditions
using either a 4% (a and b) or an 8% (c and d) polyacrylamide SDS gel.
Cell extracts were obtained from lanes 1, AB110-6L1/16L2; lanes 2,
JSC310-16L1/6L2; lanes 3, a mixture of pellets from the two haploid
strains; lanes 4, AB/JS-4L. Arrows in a and b indicate bands corre-
sponding to L1 trimers. Molecular mass standards (in kDa) are indi-
cated.
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Analysis of VLPs purified from the diploid strain
The cell extract from the yeast diploid strain was
subjected to CsCl gradient sedimentation, and pooled
fractions with a density of 1.29–1.3 mg/ml were analyzed
by Western blot, confirming the presence of HPV-6 and
HPV-16 L1 and L2 proteins (Fig. 4). Electron microscopy
(EM) analysis of the enriched fraction revealed the pres-
ence of VLPs which appeared to be similar to control
VLPs formed by either HPV-6 or HPV-16 L1 (Figs. 5a–5c).
To establish whether the two L1 proteins were assem-
bled into the hybrid VLPs according to their expression
levels in the diploid strain, defined amounts of the cell
lysate and of purified VLPs were blotted and tested with
anti-HPV-6 and -HPV-16 L1 Mabs. Signals below satura-
tion obtained from each sample using the type-specific
Mabs were scanned and the ratios between them were
calculated. The observation that the ratios obtained from
the extract and the VLPs were very similar strongly sug-
gested that neither L1 was preferentially incorporated in
the course of assembly (Figs. 5d and 5e). A similar
analysis, carried out with serial dilutions of hybrid VLPs
and of quantified HPV-6 and HPV-16 VLPs, revealed that
the ratio between the 6 and the 16 L1s in the hybrid
particles purified from the yeast clone that we had cho-
sen was approximately 1.5, with no significant changes
between the two different preparations from the same
clone (data not shown).
A direct detection of the two proteins by means of
immuno-EM (IEM) was then attempted to prove that the
HPV-6 and HPV-16 L1 proteins coassembled into VLPs.
While we were able to obtain convincing results by using
the anti-HPV-6 conformational Mab H6.B10.5 (Chris-
tensen et al., 1996b), we failed to get reproducible sig-
nals with both HPV-16 control and HPV-6/16 VLPs (not
shown) by using the anti-HPV-16 conformational Mab
H16.V5 (Christensen et al., 1996a). To overcome this
problem, we performed immunoprecipitation experi-
ments using the specific anti-HPV-6 and anti-HPV-16 L1
conformationally dependent Mabs and VLPs purified un-
der experimental conditions (see Materials and Meth-
ods) intended to reduce the possibility of aggregation of
homooligomeric capsids, if present. Western blot analy-
sis carried out with the immunoprecipitates detected
both L1 proteins when VLPs purified from the diploid
strain were used (Figs. 5f and 5i). On the contrary, when
HPV-6 and HPV-16 VLPs were copurified under identical
experimental conditions from a yeast pellet mixture of
the two haploid strains, either HPV-6 or HPV-16 L1 was
detected, depending on the type specificity of the Mab
used for the immunoprecipitation (Figs. 5g and 5j).
To find out whether 6L1/16L1 mixed capsomeres could
contribute to the formation of hybrid VLPs, immunopre-
FIG. 5. Analysis of CsCl purified VLPs. HPV-6 (a), HPV-16 (b), and
HPV-6/16 (c) VLPs were adsorbed onto Formvar–carbon-coated grids,
stained with 4% uranyl acetate, and examined under a Zeiss EM10C
microscope at a magnification of 100,000. Serial dilutions of total cell
extract from the diploid clone (d) and the purified VLPs (e) were blotted
and analyzed with type-specific anti-L1 Mabs. Numbers between slots
represent the ratios obtained by scanning signals below saturation.
The 1.29 g/cm3 CsCl gradient fractions obtained from the AB/JS-4L (f
and i) clone and from the AB/JSC-4LC (h and k) clone were immuno-
precipitated and Western blot analysis was performed. As a control, a
preparation of copurified HPV-6 and HPV-16 VLPs was used (g and j).
FIG. 4. Analysis of fractions from CsCl gradient sedimentation of
AB/JS-4L cell extracts. Aliquots of fractions with a density of 1.29–1.3
mg/ml (lanes 3) were subjected to SDS–PAGE, electroblotted on nitro-
cellulose filters, and incubated either with anti-HPV-6 L1 (a) and anti-
HPV-16 L1 (b) Mabs or with HPV-6 L2 (c) and HPV-16 L2 (d) antisera. As
a control, total cell extracts from the JSC310-6L1epi and JSC310-16L1epi
strains (lanes 1 and 2, respectively, in a and b) and the JSC310-6L2epi
and JSC310-16L2epi strains (lanes 1 and 2, respectively, in c and d)
were used. Molecular mass standards (in kDa) are indicated. Arrows
identify bands thought to represent the L2 proteins.
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cipitation experiments were carried out using the 1.29
g/cm3 CsCl gradient fraction obtained by processing the
cell extract of the diploid strain AB/JSC-4LC, in which
HPV-6 and HPV-16 L1s were respectively mutagenized at
cysteine residues C423 and C428, which should have
allowed capsomeres but not VLP assembly. Again, both
L1 proteins could be detected independently of the type
specificity of the Mab used for the immunoprecipitation
(Figs. 5h and 5k).
HPV-6/16 VLPs induce an immune response against
both HPV types
To check whether HPV-6/16 VLPs were able to induce
an immune response directed against both HPV types,
HPV-6/16 VLPs were used to immunize mice, and the
resulting immune sera were tested after the third immu-
nization. HPV-6 and HPV-16 VLPs were blotted onto ni-
trocellulose filters under nondenaturing and denaturing/
reducing conditions and incubated either with type-spe-
cific conformational Mabs or with the serum from mouse
16 (S16) immunized with HPV6/16 VLPs (Fig. 6). While
control Mabs recognized only the specific, nondenatured
VLP type, the S16 serum reacted with both VLP types,
and the observation that the signal was significantly
higher without VLPs being denatured and reduced
strongly suggested that antibodies directed against con-
formational epitopes had been elicited.
DISCUSSION
The availability of papillomavirus empty particles has
allowed a number of researchers to investigate many
immunological and biophysical facets of VLPs, including
the generation of type-specific antibodies, in vitro neu-
tralization assays, and the study of how L1 monomers
interact and form the capsid-like structure. The knowl-
edge that L1 of different PV types can coassemble may
be potentially useful not only to investigate the mecha-
nisms regulating capsid assembly, disassembly, and cel-
lular uptake but also to develop novel prophylactic ap-
proaches. In fact, while immunization with a mixture of
VLPs derived from different HPV types can induce an
immune response against all of them, antibody titers and
cytokine profiles in immunized chimpanzees were
shown to be affected by the manufacturing and purifica-
tion processes used for individuals VLP types (Palker et
al., 2001). Multiple antigen delivery by using a single
biological source may therefore represent the basis for
an accessible and suitable vaccine formulation, from
both economic and regulatory viewpoints.
Although the immune response to genital HPVs is
predominantly type-specific, cross-neutralization has
been reported between HPV-6 and HPV-11 (92% amino
acid sequence identity) (Christensen et al., 1996b) and
between HPV-16 and HPV-33 (80% amino acid sequence
identity) (White et al., 1998). This may indicate the exis-
tence of some correlation between protein sequences
and structural similarities that could possibly be relevant
for the mechanism of capsid assembly. On the basis of
these considerations, the concept that HPV-6 and
HPV-16 L1 proteins can coassemble is not obvious, since
the two viruses belong to phylogenetically more distant
groups (Chan et al., 1992; Van Rast et al., 1992) and
exhibit a lower (67%) L1 amino acid sequence identity.
In this study we have reported the purification of VLPs
from a yeast strain that has been genetically engineered
to coexpress the HPV-6 and HPV-16 L1 and L2 capsid
proteins. Although we could not unequivocally detect the
two L1 proteins on individual VLPs by IEM, the results of
the immunoprecipitation experiments strongly indicate
that the purified VLPs represent the result of specific
interactions between HPV-6 and 16 L1s, rather than the
simple coexistence and aggregation of different VLP
types (even though the formation of some homooligo-
meric capsids cannot be entirely ruled out). The fact that
the L2 proteins were present in the same CsCl fractions
favors the hypothesis that they are incorporated into the
VLPs as well, since the L2 protein expressed alone
bands at a different density in CsCl gradients (Volpers et
al., 1994) and is highly sensitive to degradation (Kirn-
bauer et al., 1993). In turn, incorporation of L2 into VLPs
suggests that some stable association between the ma-
jor and the homologous minor capsid proteins deriving
from the opposite haploid contributor occurred in the
diploid strain. This would be in agreement with the fact
that an L1/L2 interaction has been suggested to be
type-specific (Roden et al., 1996a), as well as with our
observation that L2 detection in haploid strains was far
more difficult when the protein was coexpressed with the
heterologous L1 counterpart than when the homologous
L1 was present (not shown).
Several reports have discussed the importance of di-
sulfide bonds for the integrity of native bovine papilloma-
virus type 1 virions (Li et al., 1998) and VLP structures (Li
et al., 1997; Sapp et al., 1995, 1998). Li et al. (1998) have
also shown that the cysteine 424 mutant (C424) of
HPV-11 L1 in the carboxyl-terminal domain, which has
been identified as critical for capsid formation (Li et al.,
FIG. 6. Characterization of sera derived from mice immunized with
HPV-6/16 VLPs. HPV-6 and HPV-16 VLPs were dot-blotted under dena-
turing and reducing (D) and nondenaturing and nonreducing (N) con-
ditions and incubated with the type-specific conformationally depen-
dent Mabs H6.B10.5 and H16.V5 S16 and with the S16 antiserum of a
mouse immunized with HPV-6/16 VLPs.
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1997), is still able to form capsomeres but not VLPs,
indicating that this residue may be involved in interpen-
tamer bonding. The essential role of disulfide bonds has
been confirmed by a single point mutation of either C176
or C427 in HPV-33 L1 (C428 in HPV-18 L1), which con-
verts all VLP trimers into monomers, allowing capsomere
formation but not VLP assembly (Sapp et al., 1998), while
the recent data published by Fligge et al. (2001) con-
firmed that the only product of the HPV-33 L1 C427
mutation was represented by capsomers which could be
purified from a CsCl gradient at the usual 1.29 g/cm3
density. In this context, the fact that corresponding cys-
teine residues are conserved in the HPV-6 (C423) and
HPV-16 (C428) L1s suggested that, in our diploid strain,
formation of trimers by means of covalent disulfide
bonds could result from interaction among type-specific
or “mosaic” capsomeres or both. The immunoprecipita-
tion experiments using the 1.29 g/cm3 CsCl gradient
fraction from the diploid strain coexpressing the HPV-6
and HPV-16 L1 proteins in which the critical cystein
residues were mutated showed that interaction of the
two L1 proteins still occurred. This result strongly sug-
gests the existence of hybrid capsomers, with the inter-
action of HPV-6 and HPV-16 L1 being independent of the
formation of trimers, which in fact we could hardly detect
in cell extracts of the mutated haploid and derived dip-
loid strains (not shown), in agreement with what reports
for the corresponding L1 mutants have described (Li et
al., 1998; Sapp et al., 1998). Of course, contribution of
homospecific pentamers to VLP assembly cannot be
excluded. Further investigations will be required to de-
fine more clearly the structural relationships among the
two L1 proteins and the contribution of L2 to the forma-
tion of HPV-6/16 capsids.
However, irrespective of a complete knowledge of
capsid protein organization, we could also show that
immunization of mice with HPV6/16 VLPs induced con-
formational antibodies directed against both type-spe-
cific L1s. The recent immunological analysis of several
HPV VLPs, confirming the dominant role of antibodies
directed against nonlinear epitopes and the entirely gen-
otype-specific nature of the antibody response induced,
reinforces the concept that protection from different
HPVs will require vaccines including VLPs of all the
serotypes of interest (Giroglou et al., 2001). Therefore,
although we will need to perform a more detailed immu-
nogenic and antigenic characterization of the HPV-6/16
VLPs and to confirm, by using in vitro neutralization
assays, that the immune response which we have elic-
ited using these particles can actually neutralize the two
viruses, the data that we have reported open up the
possibility of testing mosaic VLPs as a new tool for
inducing an immune response against a broader spec-
trum of HPV types.
MATERIALS AND METHODS
Yeast strains
The S. cerevisiae parental haploid strains used were
JSC310 (MATa, leu2-3, ura3-52, prb1-1122, pep4-3, prc1-
407, adr1::DM15, cir°) (Hines et al., 1994) and AB110
(MAT, leu2-3-112, ura3-52, pep4-3, his4-580, cir°) (Travis
et al., 1985), provided by Vicky Hines (Chiron Corp.,
Emeryville, CA).
Site-directed mutagenesis of L1 protein genes
Both HPV-6 and HPV-16 L1 genes were mutagenized
by using the Chameleon double-stranded site-directed
mutagenesis kit (Stratagene, La Jolla, CA) and were com-
pletely sequenced. The oligonucleotides 6C.3 (ACAGGC-
CATTACCAGTCAAAAGCCCACTC) and 16C.3 (CCAGG-
CAATTGCTAGTCAAAAACATACAC) were used to change
the TGT codons (Cys) into AGT codons (Ser) in HPV-6
(Cys423) and HPV-16 (Cys428) L1s, respectively.
Construction of recombinant plasmids
DNA fragments encoding the HPV proteins were ob-
tained from available recombinant plasmids, either by
restriction enzyme digestion or by PCR amplification (Ex-
pand High Fidelity PCR System, Boehringer Mannheim,
Mannheim, Germany), and they were completely se-
quenced using an Applied Biosystems (Norwalk, CT)
Model 373 DNA sequencer. The episomal yeast expres-
sion vector pBS24.1, containing the leucine 2 (Leu2) and
uracil 3 (Ura3) selectable genes, and the derived pBS-
6L1 plasmid, expressing the HPV-6b L1 protein under the
control of the alcohol-dehydrogenase-2-glyceraldehyde-
3-phosphate-dehydrogenase (ADH2/GAP) glucose re-
pressible promoter, have been previously reported
(Greer et al., 2000). To construct the YIpAde integrative
plasmid, a 1059-bp XbaI genomic DNA fragment of the S.
cerevisiae adenine 2 (Ade2) gene was amplified by using
the PCR oligonucleotide primers 5AdeE (5-GCGGCGAAT-
TCTAGAACAGTTGGTATATTAG-3, inserting an EcoRI site)
and 3AdeP (5-GCGGCCTGCAGGGTCTAGACTCTTTTC-
CATATA-3, inserting a PstI site). The amplified DNA frag-
ment was cloned into plasmid pUC8 digested with EcoRI
and PstI, and the XbaI sites, included in the amplified DNA
fragment, were used to excise the insert for yeast transfor-
mation. To obtain the integrative YIpLys-L2 expression plas-
mids, a 1318-bp genomic DNA fragment of the S. cerevisiae
lysine 2 (Lys2) gene was amplified by using the PCR oligo-
nucleotide primers 5LysE (5-GCGGAATTCCACTAGTAAT-
TACA-3, inserting an EcoRI site) and 3LysH (5-GATGTA-
AGCTTCTACTAGTTGA-3, inserting a HindIII site). The am-
plified DNA fragment was then inserted into pUC8 digested
with EcoRI and HindIII, generating a plasmid named YI-
pLys. A BamHI DNA fragment from the pSI3 vector (Isabel
Zaror, Chiron), including the ADH2/GAP promoter, the hu-
man superoxide dismutase (SOD) gene, and the mating
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type -factor gene transcriptional termination sequence
(TMF), was cloned into the single BglII restriction site in the
Lys2 gene sequence of YIpLys, obtaining a plasmid named
YIpLys-SOD. The YIpLys-6L2 plasmid was derived from
YIpLys-SOD, replacing the NcoI-SalI DNA fragment encod-
ing the SOD gene with the NcoI-SalI DNA fragment from
pGM3Z-6L2 (Kent Thudium, Chiron) encoding the HPV-6b
L2 open reading frame (ORF). To construct the YIpLys-16L2
plasmid, the L2 gene was amplified from a cloned HPV-16
genomic DNA (kindly provided by Dennis J. McCance, Uni-
versity of Rochester, Rochester, NY) by using the PCR oli-
gonucleotide primers DT-5L2 (5-CGACACAAACGTTCTG-
CAA-3) and DT-3L2 (5-ATTAGTCGACCTAGGCAGCCAA-
GAGACATC-3), including the translation termination codon
and a SalI site. The DNA fragment obtained was digested
with SalI and cloned into a YIpLys-SOD fromwhich the SOD
coding sequence had been removed by digestion with
NcoI, filling in with Klenow enzyme and digestion with SalI.
The pBS-6L2 and pBS-16L2 episomal expression plasmids
were obtained by replacing a SacI-SalI DNA fragment from
pBS-6L1, including part of the ADH2/GAP promoter and the
entire HPV-6b L1 ORF, with SacI-SalI DNA fragments de-
rived from either YIpLys-6L2 or YIpLys-16L2, including the
corresponding promoter region and the L2 ORF. To con-
struct the pBS-16L1 episomal expression plasmid, the L1
gene was amplified from the cloned HPV-16 genomic DNA
by using the PCR oligonucleotide primers DT-5L1 (5-
TCTCTTTGGCTGCCTAGTGAGGCCA) and DT-3L1 (5-
CTAGTAATGTCGACTTACAGCTTACGTTTTTTGCG-3), com-
prising the translational termination codon and a SalI site.
The amplified DNA fragment, encoding an L1 protein iden-
tical to the one derived from clone 114/K and described by
Kirnbauer et al. (1993), was cloned into a blunt-ended pSI3
vector from which the SOD gene had been previously
removed by digestion with NcoI and SalI restriction en-
zymes and filling in with the Klenow enzyme. From this
intermediate construct, a SacI-SalI DNA fragment, including
part of the ADH2/GAP promoter and the HPV-16L1 ORF,
replaced the corresponding SacI-SalI DNA fragment in
pBS-6L1. To construct pBS-6L1C and pBS-16L1C, the
same SacI-SalI DNA fragment, mutagenized in the L1 gene,
was used to replace the corresponding fragment in the L1
episomal expression plasmids.
Generation of recombinant yeast strains
The strains JSC310-6L1epi (Greer et al., 2000), JSC310-
16L1epi, JSC310-6L2epi, and JSC310-16L2epi, expressing
the four capsid proteins by means of episomal vectors,
were obtained by transformation of the parental JSC310
strain with the expression plasmids pBS-6L1 (Greer et
al., 2000), pBS-16L1, pBS-6L2, and pBS-16L2. The JSC310-
6L2int and the AB110-16L2int strains were obtained by
transforming competent yeast cells with 5 g of the
EcoRI-HindIII-digested YIpLys-6L2 or YIpLys-16L2 inte-
grative plasmid and 1 g of the pBS24.1 episomal vector
to allow the selection of transformants. Different clones
were tested for growth onto plates of minimal medium
(MM) supplemented with -adipate to select mutants
with an inactivated Lys2 gene (Zaret and Sherman, 1985).
Correct integration into the lys2 locus was verified by
PCR analysis by using pairs of oligonucleotide primers
complementary to sequences within the expression cas-
sette and the genomic portion of the Lys2 gene. Among
the colonies expressing the L2 protein, one was chosen,
cured of the pBS24.1 plasmid, and tested for the inability
to grow in the absence of uracil and leucine. Introduction
of the episomal L1 expressing vectors into these strains
was carried out following two different strategies. AB110-
16L2int was transformed with either the pBS-6L1 or the
pBS-6L1C expression plasmid, and selection of trans-
formants on MM plates without leucine and uracil al-
lowed the isolation of the haploid strains AB110-6L1/
16L2 and AB110-6L1C/16L2. The JSC310-6L2int strain
was instead cotransformed with the pBS-16L1 expres-
sion vector and with the XbaI-digested YIpAde integra-
tive plasmid. Transformants grown on selective plates
were plated on complete yeast extract–peptone medium
(YEP) and allowed to grow at 30°C for 3–4 days until
colonies (1–2%) developed a red color due to disruption
of the ade2 locus. One of the clones, which showed
correct integration into the ade2 locus by PCR and L1
and L2 expression by Western blot analysis, was desig-
nated JSC310-16L1/6L2. Curing of this strain of the epi-
somal plasmid, followed by transformation with pBS-
16L1C, allowed isolation of the JSC310-16L1C/6L2
strain. Generation of the AB/JSC-4L and AB/JSC-4LC
diploid strains was obtained by mixing cultures, in YEP
medium containing 5% glucose, of the haploid strains
AB110-6L1/16L2 and AB110-6L1C/16L2 with JSC310-
16L1/6L2 and JSC310-16L1C/6L2, respectively. Diploid
cells were selected onto MM plates lacking histidine and
adenine.
Growth of yeast cultures and preparation of total
cell extracts
Parental yeast strains were grown in complete YEP
medium. Strains transformed with episomal vectors were
first cultured in leucine-deficient MM medium with 4%
glucose until they reached mid-log phase. Diluting these
cultures 1:50 into YEP complete medium and culturing
the cells at 30°C for 2–3 days induced expression of the
genes under the control of the ADH2/GAP glucose-re-
pressible promoter. Total cell extracts were prepared by
incubating yeast cells for 10 min on ice in 0.24 N NaOH
and 0.96% -mercaptoethanol, followed by trichloroace-
tic acid precipitation, ice-cold acetone washing, and final
suspension of the protein pellet in 100 l of protein
loading buffer. Total cell extracts to be used for immu-
noprecipitations were prepared in PBS/0.5 M NaCl and
incubated overnight at 4°C in the presence of Complete
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Protease Inhibitors (Boehringer Mannheim) and Benzo-
nase (Merck & Co., Rahway, NJ).
Purification of VLPs
Frozen yeast cell pellets were thawed in buffer con-
taining 0.1 M Tris–HCl (pH 7.5), 0.15 M NaCl, 2 mMMgCl2,
1 mM EGTA, Complete Protease Inhibitors (No. 1-697-
498, Boehringer Mannheim), and 100 units/ml Benzo-
nase Purity Grade II (Merck). Cells were disrupted by
vortexing twice for 10 min with a 5-min interval on ice, in
the presence of glass beads [G-8772 (Sigma Chemical
Co., St. Louis, MO), 0.5 ml beads per milliliter of cell
suspension] using a VWR Scientific Product (South Plain-
field, NJ) multitube vortexer. Following overnight incuba-
tion at 4°C with gentle shaking, cellular debris was
removed by a 20-min centrifugation at 2000 g, and the
supernatants were centrifuged through a 40% (w/w) su-
crose cushion (2-h centrifugation at 100,000 g). The re-
sulting pellets were suspended in PBS, applied to a
preformed CsCl gradient (1.17–1.57 g/ml), and centrifuged
for 24 h at 285,000 g. The gradients were fractionated,
and aliquots from each fraction were subjected to mea-
surement of the refractive index and Western blot anal-
ysis with type-specific anti-L1. Fractions of interest were
dialyzed against PBS. For immunoprecipitation experi-
ments, yeast supernatants were adjusted to 0.5 m NaCl
and centrifuged for 2 h at 100,000 g through a two-
component step gradient composed of 40 and 63% (wt/
wt) sucrose in PBS/0.5 M NaCl, 0.01% Triton X-100. The
material banded at the interface between the two su-
crose solutions was collected, extensively dialyzed
against PBS/0.5 M NaCl, 0.01% Triton X-100, adjusted to
30% CsCl, and centrifuged for 48 h at 285,000 g. Frac-
tions with a density of 1.29–1.3 mg/ml were dialyzed
against PBS/0.5 M NaCl.
Western and dot/slot-blot analysis
Proteins were analyzed by sodium dodecyl sulfate–
polyacrylamide gel electrophoresis (SDS–PAGE) and
Western blotting according to standard protocols. Dot /
slot-blot analysis of denatured and reduced VLPs and
cell extracts was carried out by boiling the samples for 5
min in the presence of dithiothreitol (DTT). When the
native VLP structure had to be maintained, VLPs in PBS
were blotted without boiling and in the absence of DTT.
Reaction with HPV-specific antibodies was detected us-
ing an enhanced chemiluminescence Western blotting
reagent (Amersham, Arlington Heights, IL).
Monoclonal and polyclonal antibodies
The H6.C6 and H16.H5 monoclonal antibodies, which
bind to denatured HPV-6 and HPV-16 L1 proteins, re-
spectively, in addition to the H6.B10.5 and H16.V5 Mabs,
specific for HPV-6 and HPV-16 intact VLPs, have been
described by Christensen et al. (1996a,b). HPV-16 L2
rabbit antiserum was a gift of Lutz Gissmann (DKFZ,
Heidelberg, Germany), while HPV-6 L2 rabbit antisera
were kindly provided by Denise Galloway (Fred Hutchin-
son Cancer Research Center, Seattle, WA) and Robert C.
Rose (University of Rochester). Anti-rabbit and anti-
mouse peroxidase-conjugated antibodies were from Bio-
source International (Camarillo, CA).
Immunoprecipitations
Aliquots of either total cell extracts or CsCl-derived
gradient fractions, both in PBS/0.5 M NaCl, were immu-
noprecipitated overnight at 4°C with either of the two
type-specific conformationally dependent Mabs
H6.B10.5 (anti-HPV-6 L1) and H16.V5 (anti-HPV-16 L1).
Immune complexes were collected with Protein G
Sepharose CL-4B (Pharmacia Biotech, Piscataway, NJ),
washed 5 times with 1 ml PBS/0.5M NaCl, suspended in
40 l sample buffer without DTT, boiled for 5 min, and
subjected to SDS–PAGE and Western blot analysis using
type-specific anti-L1 Mabs.
Mouse immunization with VLPs
Six-week-old female Balb/c mice were injected sub-
cutaneously with 20 g of HPV-6/16 purified VLPs ad-
ministered with an equal volume of MF59 adjuvant (Ott et
al., 1995). A group of control mice was injected with
MF59 only. The mice were boosted with 15 g of the
antigen at week 3 and 10 g at week 5. Serum samples
were collected on day 12 after the final booster and
assayed for capsid protein-specific antibodies.
Nucleotide sequence accession numbers
The HPV-6b L1 and L2 sequences used were identical
to those derived from the HPV-6b genome deposited
in the GenBank/EMBL database under Accession No.
X00203. The HPV-16 L2 protein sequence corresponded
to that derived from the HPV-16 genome deposited in the
GenBank/EMBL database under Accession No. K02718.
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